Navigation Links
Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
Date:12/7/2009

M.D. added, "While SOLESTA is already available in Europe, we are confident that the publication of the study will enhance the adoption of this important treatment among the European professional community to help patients suffering from this condition."

About the Study

The Investigational Device Exemption Study was a randomized, subject and evaluator blinded, controlled, multi-center study designed to evaluate the efficacy and safety of SOLESTA for the treatment of fecal incontinence. More than 200 patients suffering from fecal incontinence were included in 13 study sites throughout the United States and Europe. Primary endpoints of the study looked at the efficacy of both groups at six months as well as evaluated the durability of response in the SOLESTA treatment group at 12 months.

About SOLESTA(TM)

SOLESTA is approved for use in Europe and Canada as an injectable treatment for fecal incontinence. SOLESTA is a biocompatible substance composed of stabilized hyaluronic acid, including dextranomer, manufactured according to Q-Med AB's patented technology, NASHA(TM). The treatment is a minimally invasive, in-office procedure. SOLESTA was developed in 2004 by Q-Med AB in Sweden. Oceana Therapeutics acquired the global rights to market and sell SOLESTA in June 2009.

About Q-Med AB

Q-Med is a medical device company that primarily develops, manufactures, markets and sells medical implants. Most of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The company today has approximately 650 co-workers in 20 countries, with approximately 400 at the company's head office and production facility in Uppsala. Q-Med had sales of 1,272 MSEK during 2008. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

About Oceana Therapeutics, Inc.

Oceana Therapeutics was
'/>"/>

SOURCE Oceana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... financial results for the fourth quarter and fiscal year ... Completed construction of new global headquarters ... relocated entire staff (December 2010) Appointed Dr. Ramin ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... and Chief Executive Officer, will provide an overview and update ... Healthcare Conference on Tuesday, September 13, 2011 at 1:35 pm ... York City. The presentation will be webcast live and can ...
Cached Medicine Technology:Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 2Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 3Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 4Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 5Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 6Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 7Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 8Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 9Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 10
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral ... caskets are selling well in the global market. Recently, the ... and launched a special offer for all the newly ... the company’s cherry caskets are made with superb materials. As ... people to show respect to the departed saint. MillionaireCasket.com is ...
(Date:7/13/2014)... get the best treatment and variations in the quality ... for blood cancer patients still varies widely between regions ... survival in European adults to date, published in ... that 5-year survival for most cancers of the blood ... reflecting the approval of new targeted drugs in the ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... direct marketing promotional products company, offers a specialty store filled ... ... Lewiston, ME (PRWEB) February 19, 2009 -- Crestline ... that trades on its easy, customer-friendly ordering process, offers ...
... Natrecor for a Use Not Approved By the Food ... has intervened in two whistleblower suits filed in the ... Inc. and its parent company, Johnson & Johnson Inc., ... for a use not approved by the Food and ...
... Indicates a 40% Reduction of Intraocular Pressure at Two ... today that it has surpassed 1000 implantation procedures with ... reduces intraocular pressure (IOP) for the treatment of glaucoma. ... President and Founder of SOLX, "as it validates the ...
... to Consumer-Directed Health Plans Continues, Watson Wyatt/National Business Group ... expect health care cost increases to hold steady at ... plans (CDHPs) in 2010 in an effort to control ... Wyatt, a leading global consulting firm, and the National ...
... to risk-taking, too, study finds, , , THURSDAY, Feb. ... makes people love skydiving, mountain-climbing or other intense ... the brain that has been linked to addictive ... researchers studied volunteers who were grouped as either ...
... percent less likely than men to receive a critical ... stroke, according to a Michigan State University study. , ... Diego at the International Stroke Conference, organized by the ... plasminogen activator, or tPA, first approved as a treatment ...
Cached Medicine News:Health News:Crestline is the Source for Great Green Giveaways 2Health News:Crestline is the Source for Great Green Giveaways 3Health News:United States Joins Suits Against Scios and Johnson & Johnson 2Health News:United States Joins Suits Against Scios and Johnson & Johnson 3Health News:SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 3Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: